Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and biologics, with a strong presence in oncology, vaccines, and infectious diseases. Its competitive position is bolstered by its robust pipeline, particularly in immuno-oncology with Keytruda, which has generated significant revenue across multiple indications.
Merck generates revenue primarily through the sale of prescription drugs, with a strong emphasis on oncology and vaccines. The company benefits from pricing power due to its innovative products and established market presence, allowing it to maintain high gross margins. Its competitive advantages include a diversified product portfolio and a strong R&D pipeline.
Keytruda sales growth, particularly in new indications
Regulatory approvals for new drugs in the pipeline
Market share changes in the oncology segment
Emerging data from clinical trials impacting future drug potential
Regulatory changes impacting drug pricing and approval processes
Technological disruption in drug development and delivery
Increased competition from generic drugs and biosimilars
Emerging biotech firms developing novel therapies
Moderate debt levels (Debt/Equity of 1.29) could pose risks if cash flows decline
Potential pension obligations affecting liquidity
moderate - Merck's performance is somewhat tied to GDP growth as healthcare spending tends to rise during economic expansions.
Rising interest rates can increase Merck's financing costs for R&D and acquisitions, potentially impacting its valuation multiples.
minimal - Merck's operations are not heavily reliant on credit markets.
growth - due to the potential for significant revenue growth from innovative drug development.
moderate - historically, Merck has exhibited lower volatility compared to the broader market.
